Delivery of Liposomal Doxorubicin (Doxil) in a Breast Cancer Tumor Model: Investigation of Potential Enhancement by Pulsed-High Intensity Focused Ultrasound Exposure

2006 ◽  
Vol 13 (4) ◽  
pp. 469-479 ◽  
Author(s):  
Victor Frenkel ◽  
Amena Etherington ◽  
Maiya Greene ◽  
Jade Quijano ◽  
Jianwu Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Liposomal Doxorubicin ◽  
Tumor Model ◽  
High Intensity Focused Ultrasound ◽  
Model Investigation ◽  
Ultrasound Exposure ◽  
Cancer Tumor

scholarly journals Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e040162
Author(s):  
Josanne S de Maar ◽  
Britt B M Suelmann ◽  
Manon N G J A Braat ◽  
P J van Diest ◽  
H H B Vaessen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance ◽  
Phase I ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Liposomal Doxorubicin ◽  
De Novo ◽  
Stage Iv ◽  
High Intensity Focused Ultrasound ◽  
Induced Hyperthermia

IntroductionIn breast cancer, local tumour control is thought to be optimised by administering higher local levels of cytotoxic chemotherapy, in particular doxorubicin. However, systemic administration of higher dosages of doxorubicin is hampered by its toxic side effects. In this study, we aim to increase doxorubicin deposition in the primary breast tumour without changing systemic doxorubicin concentration and thus without interfering with systemic efficacy and toxicity. This is to be achieved by combining Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox, Celsion Corporation, Lawrenceville, NJ, USA) with mild local hyperthermia, induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU). When heated above 39.5°C, LTLD releases a high concentration of doxorubicin intravascularly within seconds. In the absence of hyperthermia, LTLD leads to a similar biodistribution and antitumour efficacy compared with conventional doxorubicin.Methods and analysisThis is a single-arm phase I study in 12 chemotherapy-naïve patients with de novo stage IV HER2-negative breast cancer. Previous endocrine treatment is allowed. Study treatment consists of up to six cycles of LTLD at 21-day intervals, administered during MR-HIFU-induced hyperthermia to the primary tumour. We will aim for 60 min of hyperthermia at 40°C–42°C using a dedicated MR-HIFU breast system (Profound Medical, Mississauga, Canada). Afterwards, intravenous cyclophosphamide will be administered. Primary endpoints are safety, tolerability and feasibility. The secondary endpoint is efficacy, assessed by radiological response.This approach could lead to optimal loco-regional control with less extensive or even no surgery, in de novo stage IV patients and in stage II/III patients allocated to receive neoadjuvant chemotherapy.Ethics and disseminationThis study has obtained ethical approval by the Medical Research Ethics Committee Utrecht (Protocol NL67422.041.18, METC number 18-702). Informed consent will be obtained from all patients before study participation. Results will be published in an academic peer-reviewed journal.Trial registration numbersNCT03749850, EudraCT 2015-005582-23.

scholarly journals High-intensity focused ultrasonic ablation of breast cancer

2018 ◽  
Vol 5 (3) ◽  
pp. 67-76
Author(s):  
L. I. Moskvicheva
Keyword(s):  
Breast Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Malignant Tumors ◽  
High Intensity Focused Ultrasound ◽  
Ultrasound Therapy ◽  
Technical Success ◽  
Short Term ◽  
Technical Safety ◽  
Complete Tumor

Breast cancer is the most frequent and socially signifi cant malignant tumor disease of the female popula on of the Russian Federa on. At present, for the treatment of this pathology, the methods of the organ-preserving surgical manual allowing to achieve the maximum cosme c eff ect along with the observance of the principles of cancer safety are ge  ng more and more developed,. In recent decades, researchers from diff erent countries demonstrate the feasibility and technical safety of various mini-invasive methods of thermal abla on of early stages of breast cancer, characterized by rela ve simplicity of implementa on, excellent cosme c results, short-term rehabilita on of pa ents. These include hyperthermic techniques (radiofrequency, microwave, laser abla on) and hypothermic method (cryoabla on). Each technique has unique characteris cs of impact on the tumor and is performed under the control of ultrasound, computer tomography or magne c resonance imaging. The technical success of these abla on techniques is achieved in 93–98% of cases. Complete tumor necrosis a er radiofrequency abla on is observed in 76–100% of pa ents with breast cancer, laser abla on – in 13–76%, microwave abla on – in 0–8%, cryoabla on – in 36–83%. The frequency of development of specifi c complica ons of local thermal destruc on is 4–13%. To date, there is only one method of noninvasive extracorporeal thermal abla on of tumors of diff erent localiza on – high-intensity focused ultrasound therapy, the eff ec veness and safety of which as a method of local destruc on of benign and malignant tumors of the breast demonstrated by many authors. Like all methods of thermal abla on, high-intensity focused ultrasound therapy has its limita ons, complica ons and disadvantages. This ar cle presents a literary review that highlights the possibili es of this method of local destruc on in pa ents with malignant tumors of the breast.

Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer

2015 ◽  
Vol 102 (8) ◽  
pp. 873-882 ◽  
Author(s):  
M. C. L. Peek ◽  
M. Ahmed ◽  
A. Napoli ◽  
B. ten Haken ◽  
S. McWilliams ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Ultrasound Ablation ◽  
Focused Ultrasound Ablation
Sign in / Sign up

Export Citation Format

Share Document